Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.
- Trial name
- NCT01546818
- Testing
- SAV001-H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumagen
HIV Infections
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults.
- Trial name
- NCT04871113
- Testing
- GSK3810109A, Dolutegravir+lamivudine SOC regimen
- Where
- 24 sites in United States, Argentina and 4 more
- Volunteers
- 62 people
- Sponsor
- ViiV Healthcare
HIV/AIDS, HIV-1-infection
Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)
This is an open-label, randomized pilot study to assess the effect on bone mineral density (BMD) of a switch from a tenofovir alafenamide-containing antiretroviral regimen to dolutegravir/lamivudine vs.
- Conditions
- HIV/AIDS, HIV-1-infection, Osteopenia
- Trial name
- ReNew (NCT03549689)
- Testing
- Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC), Current tenofovir alafenamide (TAF)-containing ART regimen
- Where
- 10 sites in United States
- Sponsor
- Philip Grant
HIV-1-infection
Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.
Phase IIa, open clinical trial, pilot, single arm and proof of concept.
- Trial name
- NCT03539224
- Testing
- Dolutegravir (DTG), Lamivudine (3TC)
- Where
- 2 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
HIV Infections
Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems
The purpose of this study is to see if children and young adults with better immune systems before starting highly active antiretroviral therapy (HAART) do better than those who have weaker immune systems before starting HAART.
- Trial name
- NCT00001097
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Methamphetamine-dependence, HIV-1-infection
Contingency Management for PrEP Adherence and/or Methamphetamine Use
Use of crystal methamphetamine (MA) leads to changes in sexual risk behavior, adherence to HIV prevention tools, immune response to infection, and tissue inflammation that collectively increase risk for HIV transmission among…
- Trial name
- C-MAX (NCT04563962)
- Testing
- Contingency Management-ART, Contingency Management-Methamphetamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Healthy, HIV Infections
HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers
This study will test the safety and side effects of an experimental vaccine booster against HIV. A vaccine is a substance given to try to create immunity or resistance to a disease or infection.
- Trial name
- NCT00102089
- Testing
- VRC-HIVADV014-00-VP booster, VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults
The purpose of this study is to evaluate the safety and tolerability of an HIV-1 nef/tat/vif, env pDNA vaccine delivered with electroporation (EP), followed by a recombinant vesicular stomatitis virus (rVSV) HIV envC vaccine…
- Trial name
- NCT02654080
- Testing
- HIV-1 nef/tat/vif, env pDNA vaccine, rVSV HIV envC vaccine
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
The objective of the study is to compare two different doses of Peg-INF-α-2A (90 or 180 ug/wk) for their ability to maintain viral control when initiated 5 weeks before ART (antiretroviral therapy) interruption in HIV positive…
- Trial name
- NCT00594880
- Testing
- Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- The Wistar Institute
HIV
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination
This is a clinical proof-of-concept (PoC) study of DNA vaccination after SAP depletion. The investigators will measure the immune responses to DNA vaccination against HIV-1 in healthy adult male volunteers, comparing a group in…
- Trial name
- HIV-CORE003 (NCT02425241)
- Testing
- pSG2.HIVconsv DNA vaccine, ChAdV63.HIVconsv booster vaccine, MVA.HIVconsv booster vaccine
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University College, London
HIV Infections
Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs
For a few years, there has been a keen interest of clinicians and patients for "lighter" antiretroviral strategies based on two- or even single drug regimens rather than the canonical triple therapy, both as initial and…
- Trial name
- IDOLTIB (NCT04034862)
- Testing
- Treatment simplification (dolutegravir lamivudine)
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- University of Liege
Human Immunodeficiency Virus Type 1
A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study
The purpose of this study is to evaluate the long-term safety and tolerability of etravirine, administered as part of an individually optimized antiretroviral therapy (ART), in human immunodeficiency virus Type 1 (HIV-1) infected…
- Trial name
- NCT00128830
- Testing
- Etravirine (ETR), Nucleotide reverse transcriptase inhibitors (NRTIs), Protease inhibitors (PIs)
- Volunteers
- 211 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection
Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
The primary objective of this study is to evaluate the steady state PK of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination (FDC) in HIV-1 infected…
- Trial name
- NCT03960645
- Testing
- B/F/TAF
- Where
- 8 sites in United States, Dominican Republic and 1 more
- Volunteers
- 62 people
- Sponsor
- Gilead Sciences
HIV-1, Public Universal Healthcare Insurance Coverage
Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity Settings in France -IMEA073
In France, French citizens with an annual income less than 10339 euros are considered living with low-income and are eligible to benefit from a public universal healthcare insurance coverage called C2S (complémentaire santé…
- Conditions
- HIV-1, Public Universal Healthcare Insurance Coverage, BIC/FTC/TAF, Low Income Population
- Trial name
- PRECARITY (NCT07122557)
- Testing
- Biktarvy
- Volunteers
- 320 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV Infections
Regional Bone Turnover Using 18F-fluoride-PET/CT in HIV-1-infected Men: PETRAM Study
This is a 48 week study to explore the pathogenesis of HIV treatment related bone disease by using a novel imaging technique, 18F-Fluoride Positron Emission Tomography (18F-PET/CT), which measures regional bone formation.
- Trial name
- PETRAM (NCT03405012)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University College, London
HIV Infections
Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication
Patients infected and living with HIV are getting older and have more and more non-HIV co-morbidities. These expose them to polypharmacy that increases the risk of pharmacological interaction.
- Trial name
- BICOLDER (NCT04222283)
- Testing
- BIKTARVY 50Mg-200Mg-25Mg Tablet
- Where
- 8 sites in France
- Volunteers
- 27 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV-1-infection
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
The goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) is versus continuing a daily oral HIV treatment in…
- Trial name
- NCT07683000
- Testing
- Lenacapavir, Lenacapavir Tablet, Teropavimab
- Where
- 2 sites in United States
- Volunteers
- 590 people
- Sponsor
- Gilead Sciences
Pre-Exposure Prophylaxis of HIV-1 Infection
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or…
- Trial name
- DISCOVER (NCT02842086)
- Testing
- F/TAF, F/TDF
- Where
- 93 sites in United States, Austria and 9 more
- Volunteers
- 5,399 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
The purpose of this study was to evaluate the safety and immunotherapeutic activity of an anti-PD-1 antibody (cemiplimab) in participants with HIV-1 on suppressive combination antiretroviral therapy (cART).
- Trial name
- NCT03787095
- Testing
- Cemiplimab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Providing Unique Support for Health (PUSH) Study
Project Narrative This 5-city proposal seeks to address HIV disparities among young (ages 15-24) Black and/or Latinx men who have sex with men (YBLMSM) and transgender women (YBLTW) in a multilevel intervention to identify…
- Trial name
- NCT03194477
- Testing
- Mobile-enhanced Engagement Intervention
- Where
- United States
- Volunteers
- 631 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.